Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) Director Julia Haller sold 3,800 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director owned 30,279 shares of the company's stock, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Bristol Myers Squibb Stock Performance
NYSE BMY traded down $0.93 during trading on Friday, reaching $62.20. The company's stock had a trading volume of 9,794,555 shares, compared to its average volume of 12,156,425. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The firm has a market cap of $127.15 billion, a price-to-earnings ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a twelve month low of $45.26 and a twelve month high of $68.64. The business's fifty day moving average price is $62.34 and its 200-day moving average price is $60.11.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same quarter in the prior year, the firm earned $1.63 earnings per share. The business's quarterly revenue was up 6.9% compared to the same quarter last year. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.
Bristol Myers Squibb Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 55.88%.
Institutional Trading of Bristol Myers Squibb
Several hedge funds have recently modified their holdings of the business. Cornerstone Advisory LLC boosted its holdings in Bristol Myers Squibb by 4.4% during the third quarter. Cornerstone Advisory LLC now owns 6,872 shares of the biopharmaceutical company's stock worth $429,000 after buying an additional 287 shares in the last quarter. Ibex Wealth Advisors purchased a new stake in shares of Bristol Myers Squibb during the 3rd quarter worth approximately $4,641,000. Addison Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 117.1% during the 3rd quarter. Addison Advisors LLC now owns 1,192 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 643 shares in the last quarter. Hamel Associates Inc. acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth approximately $224,000. Finally, BankPlus Trust Department grew its holdings in shares of Bristol Myers Squibb by 4.3% in the 3rd quarter. BankPlus Trust Department now owns 33,972 shares of the biopharmaceutical company's stock worth $2,120,000 after acquiring an additional 1,409 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on BMY shares. Rothschild & Co Redburn boosted their target price on Bristol Myers Squibb from $51.00 to $53.00 and gave the company a "neutral" rating in a report on Thursday, October 8th. Wells Fargo & Company decreased their price target on Bristol Myers Squibb from $65.00 to $60.00 and set an "equal weight" rating for the company in a report on Tuesday, October 13th. Citigroup reiterated a "neutral" rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. The Goldman Sachs Group raised shares of Bristol Myers Squibb from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 16th. Finally, Raymond James Financial began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "strong-buy" rating for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $65.46.
Read Our Latest Stock Analysis on BMY
Key Headlines Impacting Bristol Myers Squibb
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
- Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
- Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
- Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
- Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?
Bristol Myers Squibb Company Profile
(
Get Free Report)
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.
The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
